| Clinical data | |
|---|---|
| Other names | KBP-5074 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| UNII | |
| Chemical and physical data | |
| Formula | C28H30ClN5O2 |
| Molar mass | 504.03 g·mol−1 |
Ocedurenone, formerly known asKBP-5074,[1] is a nonsteroidal, selectivemineralocorticoid receptor antagonist that is being developed to treathypertension in patients withchronic kidney disease with less risk ofhyperkalemia than existing treatments.[2][3] In 2023, KPB Biosciences entered into talks to sell the drug toNovo Nordisk for up to USD$1.3 billion. It is asmall molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.[4][5]
Thisantihypertensive-related article is astub. You can help Wikipedia byadding missing information. |